What are the Historical Developments and Current Growth Metrics of the Migraine Treatment Market?
The migraine treatment market has seen considerable growth due to a variety of factors.
• There has been significant growth in the migraine treatment market in the past few years. The market, which is projected to increase from $3.18 billion in 2024 to $3.48 billion in 2025, is expected to experience a compound annual growth rate (CAGR) of 9.4%. This impressive growth during the historic period is a result of several factors including a higher incidence of migraines, increased spending on healthcare, enhancements to existing drug formulas, growth in clinical research, and the development of new treatment methods.
What Is The Projected Growth Of The Migraine Treatment Market?
The Migraine Treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for migraine treatments is forecasted to experience substantial growth in the coming years, escalating to $5.32 billion in 2029 with a compound annual growth rate (CAGR) of 11.2%.
This growth over the forecast period is expected to be driven by factors such as increasing awareness and education, the introduction of monoclonal antibodies, amplified attention towards pediatric migraines, proliferation of non-pharmacological interventions, global efforts towards migraine research. The forecast period is also likely to see notable trends such as progress in therapeutic strategies, utilization of wearable devices and digital therapeutics, uptake of telemedicine and remote consultations, an emphasis on patient-centric care models, growth in the generic drug market, and the use of oral CGRP inhibitors.
What Are The Key Drivers Fueling Growth In The Migraine Treatment Market?
The continuous interaction with electronic screens, known as prolonged screen exposure, is anticipated to drive the growth of the migraine treatment market. This includes exposure to screens such as smartphones, tablets, computers, and televisions. The contribution to longer screen times is due to factors like the rise in remote work, online education, digital entertainment, and an increasing dependency on technology for social engagements. Managing migraine symptoms triggered or aggravated by this extended screen interaction, involves methods such as medication intakes, lifestyle changes, and adherence to ergonomic principles to reduce strain and avert episodes. For example, a report from the House of Commons Committee, a health organization based in the UK Parliament, reported in May 2024 that children's screen time rose by 52% in 2022. Almost 25% of children and adolescents displayed smartphone usage patterns characteristic of behavioral addiction. Consequently, such extensive screen exposure is propelling the growth of the migraine treatment market.
What Are The Principal Market Segments In The Global Migraine Treatment Industry?
The migraine treatment market covered in this report is segmented –
1) By Types: Episodic, Migraine With Aura, Chronic, Other Types
2) By Treatment: Acute Or Abortive Treatment, Preventive Or prophylactic Treatment, Non-Pharmacological Therapies And Devices
3) By End-User: Hospitals, Clinics, Homecare, Other End-users
Subsegments:
1) By Episodic: Frequent Episodic Migraine, Infrequent Episodic Migraine
2) By Migraine With Aura: Visual Aura, Sensory Aura, Speech Or Language Aura
3) By Chronic: Chronic Migraine Without Aura, Chronic Migraine With Aura
4) By Other Types: Hemiplegic Migraine, Retinal Migraine, Menstrual Migraine, Other Specific Types
Pre-Book The Migraine Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Migraine Treatment Industry?
A key trend emerging in the migraine treatment market is the emphasis on product innovations. Leading companies in the industry are unveiling innovative products like liquid formulations to consolidate their market stand. BioDelivery Sciences International (BDSI), an American pharmaceutical firm, is a case in point. In January 2022, it debuted its new product, Elyxyb (celecoxib oral solution), intended to treat acute migraines in adults irrespective of their aura manifestation. Elyxyb's liquid formulation ensures swift absorption in the small intestine, providing quicker relief than conventional tablet forms. This is particularly useful for migraine patients dealing with nausea or vomiting as it does away with the need for a pill to dissolve. Elyxyb, being the first and only FDA-approved ready-to-use oral solution for migraines, offers a more manageable and effective treatment alternative for handling the severe pain affiliated with migraines.
Who Are the Key Players In The Migraine Treatment Market?
Major companies operating in the migraine treatment market include:
• Pfizer Inc.
• Eli Lilly and Company
• Amgen Inc.
• GlaxoSmithKline PLC
• Novartis AG
• Bayer AG
• Allergan PLC
• Abbott Laboratories
• Allodynic Therapeutics LLC
• AOBiome LLC
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• Dr. Reddy's Laboratories Limited
• Impel Pharmaceuticals Inc.
• AbbVie Inc.
• Alder BioPharmaceuticals Inc.
• Astellas Pharma Inc.
• Biohaven Pharmaceutical Holding Company Ltd.
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Endo International PLC
• Impax Laboratories Inc.
• Johnson & Johnson Inc.
• Lannett Company Inc.
• Lupin Limited
• Merck & Co. Inc.
• Mylan N.V.
What Are The Regional Insights Into The Migraine Treatment Market?
North America was the largest region in the migraine treatment market in 2024. The regions covered in the migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
